Business Wire

PUMA

24.5.2023 11:29:32 CEST | Business Wire | Press release

Share
PUMA Made 7 Out of 10 Products from Better Materials In 2022

Sports company PUMA made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005783/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sports company PUMA has made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials. (Photo: Business Wire)

Better materials, such as cotton and viscose from certified sources or recycled polyester, have a smaller environmental footprint in terms of CO2 emissions and allow PUMA to improve its environmental impact across its product range. Since 2017, we have been able to reduce PUMA’s CO2 emissions from materials by 32%. Overall CO2 emissions could be reduced by 7%*, despite a significant growth in sales..

“Our Forever Better strategy aims to make PUMA better across the entire value chain, whether it comes to materials, carbon emissions, circularity or human rights,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We know there is still a lot of work to be done, but we are encouraged by the progress we made last year.”

While PUMA, which is on track to reach its goal of making 9 out of 10 products with better materials by 2025, continued to power 100%* of its offices, stores and warehouses with renewable energy in 2022, its suppliers also increased the use of renewable energy in the supply chain, where most of PUMA’s carbon emissions originate.

PUMA’s core suppliers, which represent approximately 80% of PUMA’s production volume, more than doubled their consumption of renewable energy in just one year, from 0.2% in 2017 to 11% in 2022. This was achieved through the installation of large-scale solar power systems at selected suppliers and the purchase of renewable energy certificates. By 2025, PUMA aims to more than double this figure once again and get its core suppliers to source a quarter of their energy needs from renewable sources.

More than 50% of the polyester used in PUMA’s apparel and accessories came from recycled materials and the company also started to scale up the use of recycled cotton.

At the same time, PUMA made progress with its Forever Better experiments RE:SUEDE, which tests for a biodegradable sneaker, and RE:FIBRE, which aims to scale up more advanced polyester recycling technologies. Both projects continue in 2023.

To ensure that the rights of the more than half a million workers in PUMA’s supply chain were upheld, the company collected audit reports from 510 factories producing finished products and materials in 2022.

PUMA’s sustainability report is available at https://annual-report.puma.com.. As a result of the feedback PUMA received during its first “Conference of the People” in London in 2022 and to reach out to young audiences, parts of the sustainability report will also be made available as a podcast on Spotify, launching June 1, 2023.

*Including renewable energy attribute certificates

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005783/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye